ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 0975

Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1363

Prevalence and Predictors of Orthopaedic Surgery in Rheumatoid Arthritis After 12-Years’ Follow-Up (ESPOIR Cohort)

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1565

Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study

Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1434

Prevalence of Liver Steatosis in Axial Spondyloarthritis : A Retrospective Study Using Computed Tomography Liver Minus Spleen Attenuation Ratio

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1435

Prevalence, Progression, and Associated Factors of Enthesopathy at Hip and Pelvic Regions in Patients with Axial Spondyloarthritis: Computed Tomography-based Assessment

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1563

Prevalence, Risk Factors and Associations for Osteoporosis in Postmenopausal Women with Scleroderma

Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1292

Primary Care Provider Educational Tool to Improve Osteoarthritis Management in the Primary Care Setting

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 0895

Procoagulant Extracellular Vesicles in Patients with Livedo Reticularis

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1624

Prognostic Value of Baseline 18F-FDG PET/CT Scan in Giant Cell Arteritis with Large Vessel Involvement

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1098

Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1540

Project HOPE: HydrOxychloroquine Adherence ProjEct

SLE – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1598

Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling

Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 1088

Prospective Evaluation of Carotid Atherosclerosis, Urate Deposits and Inflammation After One Year of Treatment in Newly Diagnosed Gout

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1531

Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial

SLE – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0899

Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis

Genetics, Genomics & Proteomics Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].